Status:
COMPLETED
Safety and Efficacy of ATG003 in Patients With AMD Receiving Anti-VEGF
Lead Sponsor:
CoMentis
Conditions:
Age-Related Macular Degeneration
Eligibility:
All Genders
56+ years
Phase:
PHASE2
Brief Summary
This study is a double-masked, randomized, placebo-controlled study of the safety and preliminary efficacy of ATG003 (topical mecamylamine) in patients receiving maintenance injections of either ranib...
Eligibility Criteria
Inclusion
- \> 55 years of age
- clinical diagnosis of neovascular AMD
Exclusion
- confounding ocular condition
Key Trial Info
Start Date :
May 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2010
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00607750
Start Date
May 1 2008
End Date
May 1 2010
Last Update
October 28 2010
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.